Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 529

1.

Evaluation of serum percent trisialotransferrin as potential predictive biomarker of hepatocellular dedifferentiation in chronic liver disease.

Gressner OA, Jafari S, Erkens M, Gao C, Stanzel S, Gressner AM.

Clin Chim Acta. 2009 May;403(1-2):188-93. doi: 10.1016/j.cca.2009.02.017. Epub 2009 Mar 10.

PMID:
19281805
2.

Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease?

Schöniger-Hekele M, Ramskogler K, Hartl D, Lesch OM, Müller C.

Wien Med Wochenschr. 2006 Apr;156(7-8):216-22.

PMID:
16823539
3.

Serum carbohydrate-deficient transferrin in patients with nonalcoholic liver disease and with hepatocellular carcinoma.

Murawaki Y, Sugisaki H, Yuasa I, Kawasaki H.

Clin Chim Acta. 1997 Mar 18;259(1-2):97-108.

PMID:
9086297
4.

Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease.

Newsome PN, Beldon I, Moussa Y, Delahooke TE, Poulopoulos G, Hayes PC, Plevris JN.

Aliment Pharmacol Ther. 2000 Oct;14(10):1295-301.

5.

Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma.

Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM.

Eur J Gastroenterol Hepatol. 2009 Sep;21(9):990-5. doi: 10.1097/MEG.0b013e3283293769.

PMID:
19322100
6.

Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.

Cervello M, Virruso L, Lipani G, Giannitrapani L, Soresi M, Carroccio A, Gambino R, Sanfililippo R, Marasà L, Montalto G.

J Cancer Res Clin Oncol. 2000 Jun;126(6):345-51.

PMID:
10870645
7.

Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.

Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY, Yang YF.

Anticancer Res. 1997 Jul-Aug;17(4A):2803-9.

PMID:
9252719
8.

Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.

Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF.

Clin Chim Acta. 2013 Jun 5;421:126-31. doi: 10.1016/j.cca.2013.02.029. Epub 2013 Mar 15.

PMID:
23501329
9.

Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease.

Tangkijvanich P, Kongtawelert P, Pothacharoen P, Mahachai V, Suwangool P, Poovorawan Y.

Asian Pac J Allergy Immunol. 2003 Jun;21(2):115-20.

10.

Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease.

Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H.

J Hepatol. 1999 Sep;31(3):474-81.

PMID:
10488707
11.

Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.

Jiang J, Zhang X, Wu C, Qin X, Luo G, Deng H, Lu M, Xu B, Li M, Ji M, Xu N.

Lipids Health Dis. 2008 Jul 24;7:25. doi: 10.1186/1476-511X-7-25.

12.

Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.

Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I.

Clin Biochem. 2009 Apr;42(6):455-61. doi: 10.1016/j.clinbiochem.2008.11.004. Epub 2008 Nov 27.

PMID:
19063876
13.

Serum collagenase activity in patients with chronic liver disease.

Murawaki Y, Koda M, Yamada S, Kawasaki H, Shima H, Burkhardt H.

J Hepatol. 1993 Jul;18(3):328-34.

PMID:
8228126
14.

Elevation of serum cystatin C concentrations in patients with chronic liver disease.

Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T.

Eur J Gastroenterol Hepatol. 2001 Aug;13(8):951-5.

PMID:
11507361
15.

Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?

Kara B, Doran F, Kara IO, Akkiz H, Sandikci M.

Int J Clin Pract. 2008 Aug;62(8):1206-11. doi: 10.1111/j.1742-1241.2007.01675.x. Epub 2008 Feb 18.

PMID:
18284441
16.

Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.

Murawaki Y, Yamamoto H, Kawasaki H, Shima H.

Clin Chim Acta. 1993 Sep 17;218(1):47-58.

PMID:
8299219
17.

Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma.

Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu M, Wiedenmann B, Berg T, Schott E.

Am J Gastroenterol. 2007 Nov;102(11):2471-81. Epub 2007 Jun 20.

PMID:
17581268
18.

Clinical significance of evaluation of serum zinc concentrations in C-viral chronic liver disease.

Moriyama M, Matsumura H, Fukushima A, Ohkido K, Arakawa Y, Nirei K, Yamagami H, Kaneko M, Tanaka N, Arakawa Y.

Dig Dis Sci. 2006 Nov;51(11):1967-77. Epub 2006 Oct 18.

PMID:
17048113
19.

Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma.

Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE, Gressner AM.

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):755-61.

PMID:
17700260
20.

Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma.

Biguzzi E, Franchi F, Bucciarelli P, Colombo M, Romeo R.

Thromb Res. 2007;120(2):289-93. Epub 2006 Oct 17.

PMID:
17049585
Items per page

Supplemental Content

Write to the Help Desk